Molecularly targeted therapies for acute myeloid leukemia:reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.02.004
- VernacularTitle:急性髓系白血病的分子靶向治疗：第57届美国血液学会年会报道
- Author:
Danfeng ZHANG
;
Luyang ZHANG
;
Ling PAN
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Genetic mutation;
Targeted therapy;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(2):75-78
- CountryChina
- Language:Chinese
-
Abstract:
Sina 21 century it have seen major leaps in the understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of targeted drugs against specific mutant proteins, such as FLT3-internal tandem duplications (ITD) and isocitrate dehydrogenase mutations (IDH) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets from the 57th American Society of Hematology annual meeting.
